These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 25547653)

  • 1. Lenalidomide differently modulates CD20 antigen surface expression on chronic lymphocytic leukemia B-cells.
    D'Arena G; Ruggieri V; D'Auria F; La Rocca F; Simeon V; Statuto T; Caivano A; Telesca D; Del Vecchio L; Musto P
    Leuk Lymphoma; 2015; 56(8):2458-9. PubMed ID: 25547653
    [No Abstract]   [Full Text] [Related]  

  • 2. Chemotherapy-induced augmentation of T cells expressing inhibitory receptors is reversed by treatment with lenalidomide in chronic lymphocytic leukemia.
    Gassner FJ; Zaborsky N; Neureiter D; Huemer M; Melchardt T; Egle A; Rebhandl S; Catakovic K; Hartmann TN; Greil R; Geisberger R
    Haematologica; 2014 May; 99(5):67-9. PubMed ID: 24561794
    [No Abstract]   [Full Text] [Related]  

  • 3. Increased SHISA3 expression characterizes chronic lymphocytic leukemia patients sensitive to lenalidomide.
    Maffei R; Fiorcari S; Martinelli S; Benatti S; Bulgarelli J; Rizzotto L; Debbia G; Santachiara R; Rigolin GM; Forconi F; Rossi D; Laurenti L; Palumbo GA; Vallisa D; Cuneo A; Gaidano G; Luppi M; Marasca R
    Leuk Lymphoma; 2018 Feb; 59(2):423-433. PubMed ID: 28639485
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improvement of rituximab efficiency in chronic lymphocytic leukemia by CpG-mediated upregulation of CD20 expression independently of PU.1.
    Mankaï A; Buhé V; Hammadi M; Youinou P; Ghedira I; Berthou C; Bordron A
    Ann N Y Acad Sci; 2009 Sep; 1173():721-8. PubMed ID: 19758221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Downregulation of BCL2 by AT-101 enhances the antileukaemic effect of lenalidomide both by an immune dependant and independent manner.
    Masood A; Chitta K; Paulus A; Khan AN; Sher T; Ersing N; Miller KC; Manfredi D; Ailawadhi S; Borrelo I; Lee KP; Chanan-Khan A
    Br J Haematol; 2012 Apr; 157(1):59-66. PubMed ID: 22171982
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lenalidomide-induced upregulation of CD80 on tumor cells correlates with T-cell activation, the rapid onset of a cytokine release syndrome and leukemic cell clearance in chronic lymphocytic leukemia.
    Aue G; Njuguna N; Tian X; Soto S; Hughes T; Vire B; Keyvanfar K; Gibellini F; Valdez J; Boss C; Samsel L; McCoy JP; Wilson WH; Pittaluga S; Wiestner A
    Haematologica; 2009 Sep; 94(9):1266-73. PubMed ID: 19734418
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lenalidomide interferes with tumor-promoting properties of nurse-like cells in chronic lymphocytic leukemia.
    Fiorcari S; Martinelli S; Bulgarelli J; Audrito V; Zucchini P; Colaci E; Potenza L; Narni F; Luppi M; Deaglio S; Marasca R; Maffei R
    Haematologica; 2015 Feb; 100(2):253-62. PubMed ID: 25398834
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bone marrow stromal mesenchymal cells induce down regulation of CD20 expression on B-CLL: implications for rituximab resistance in CLL.
    Marquez ME; Hernández-Uzcátegui O; Cornejo A; Vargas P; Da Costa O
    Br J Haematol; 2015 Apr; 169(2):211-8. PubMed ID: 25612644
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lenalidomide Induces Interleukin-21 Production by T Cells and Enhances IL21-Mediated Cytotoxicity in Chronic Lymphocytic Leukemia B Cells.
    Browning RL; Byrd WH; Gupta N; Jones J; Mo X; Hertlein E; Yu L; Muthusamy N; Byrd JC
    Cancer Immunol Res; 2016 Aug; 4(8):698-707. PubMed ID: 27287425
    [TBL] [Abstract][Full Text] [Related]  

  • 10. lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells.
    Wu L; Adams M; Carter T; Chen R; Muller G; Stirling D; Schafer P; Bartlett JB
    Clin Cancer Res; 2008 Jul; 14(14):4650-7. PubMed ID: 18628480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lenalidomide for the treatment of B-cell malignancies.
    Chanan-Khan AA; Cheson BD
    J Clin Oncol; 2008 Mar; 26(9):1544-52. PubMed ID: 18285605
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of FCGR3A-158V/F Genotype and Baseline CD20 Antigen Count on Target-Mediated Elimination of Rituximab in Patients with Chronic Lymphocytic Leukemia: A Study of FILO Group.
    Tout M; Gagez AL; Leprêtre S; Gouilleux-Gruart V; Azzopardi N; Delmer A; Mercier M; Ysebaert L; Laribi K; Gonzalez H; Paintaud G; Cartron G; Ternant D
    Clin Pharmacokinet; 2017 Jun; 56(6):635-647. PubMed ID: 27783363
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lenalidomide treatment of chronic lymphocytic leukaemia patients reduces regulatory T cells and induces Th17 T helper cells.
    Idler I; Giannopoulos K; Zenz T; Bhattacharya N; Nothing M; Döhner H; Stilgenbauer S; Mertens D
    Br J Haematol; 2010 Mar; 148(6):948-50. PubMed ID: 19961483
    [No Abstract]   [Full Text] [Related]  

  • 14. Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases.
    Chow KU; Sommerlad WD; Boehrer S; Schneider B; Seipelt G; Rummel MJ; Hoelzer D; Mitrou PS; Weidmann E
    Haematologica; 2002 Jan; 87(1):33-43. PubMed ID: 11801463
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lenalidomide in the treatment of chronic lymphocytic leukemia.
    Itchaki G; Brown JR
    Expert Opin Investig Drugs; 2017 May; 26(5):633-650. PubMed ID: 28388253
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutations in the 3' untranslated region of
    Bittolo T; Pozzo F; Bomben R; D'Agaro T; Bravin V; Bulian P; Rossi FM; Zucchetto A; Degan M; Macor P; D'Arena G; Chiarenza A; Zaja F; Pozzato G; Di Raimondo F; Rossi D; Gaidano G; Del Poeta G; Gattei V; Dal Bo M
    Haematologica; 2017 Aug; 102(8):e305-e309. PubMed ID: 28550186
    [No Abstract]   [Full Text] [Related]  

  • 17. Purine-rich box-1-mediated reduced expression of CD20 alters rituximab-induced lysis of chronic lymphocytic leukemia B cells.
    Mankaï A; Bordron A; Renaudineau Y; Martins-Carvalho C; Takahashi S; Ghedira I; Berthou C; Youinou P
    Cancer Res; 2008 Sep; 68(18):7512-9. PubMed ID: 18794139
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lenalidomide in lymphomas and chronic lymphocytic leukemia.
    Wiernik PH
    Expert Opin Pharmacother; 2013 Mar; 14(4):475-88. PubMed ID: 23356486
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New agents for the treatment of genetically high-risk chronic lymphocytic leukemia.
    Bazargan A; Tam CS
    Leuk Lymphoma; 2010 Jan; 51(1):3-4. PubMed ID: 20001866
    [No Abstract]   [Full Text] [Related]  

  • 20. Modulation of CD20 antigen expression after rituximab treatment: a retrospective study in patients with chronic lymphocytic leukemia.
    D'Auria F; Guariglia R; Villani O; Mansueto G; Grieco V; Zonno A; Bianchino G; Di Giovannantonio L; Vita G; Musto P
    Clin Ther; 2010 Oct; 32(11):1911-6. PubMed ID: 21095486
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.